A

Akero Therapeutics
D

AKRO

54.540
USD
-0.08
(-0.15%)
مغلق
حجم التداول
166,823
الربح لكل سهم
-4
العائد الربحي
-
P/E
-15
حجم السوق
4,489,975,230
أصول ذات صلة الأخبار المقالات
المزيد

العنوان: Akero Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.